Portage Biotech to Present at Upcoming Investor Conferences

Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company, has announced its participation in two upcoming investor conferences.

They will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 9:30 am ET and at Cantor Fitzgerald’s Oncology, Hematology, & HemeOnc Conference on September 28, 2022, at 1:45 pm ET. The management will also hold one-on-one meetings with investors at these events, emphasizing their commitment to improving treatment options and survival rates for patients with cancer.

WESTPORT, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company’s management team will be presenting at the following upcoming investor conferences:

H.C. Wainwright 24th Annual Global Investment Conference
Date / Time:	September 13, 2022 at 9:30am ET
Format:	Company Presentation

Cantor Fitzgerald’s Oncology, Hematology, & HemeOnc Conference
Date / Time:	September 28, 2022 at 1:45pm ET
Format:	Panel Presentation: Trends and Challenges in Immuno-Oncology

The Portage management team will participate in one-on-one investor meetings during each of these events. Investors interested in meeting with Portage at the conferences should contact their respective event representative.

About Portage Biotech Inc.
Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. Portage’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of six diverse platforms, with lead programs including invariant natural killer T cell (iNKT agonists) and a suite of treatments targeting the adenosine pathway. Additional programs leverage delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these six platforms, Portage has 14 products currently in development with multiple clinical readouts expected through the end of 2023. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations
Chuck Padala
chuck@lifesciadvisors.com

Media Relations
Gwendolyn Schanker
gschanker@lifescicomms.com

FAQ

When is Portage Biotech presenting at the H.C. Wainwright Annual Global Investment Conference?

Portage Biotech will present on September 13, 2022, at 9:30 am ET.

What is the focus of Portage Biotech's presentations at the conferences?

The focus is on their innovative therapies and advancements in immuno-oncology.

When is the Cantor Fitzgerald’s Oncology, Hematology, & HemeOnc Conference?

The conference is scheduled for September 28, 2022, at 1:45 pm ET.

How can investors meet with Portage Biotech during the conferences?

Investors interested in one-on-one meetings should contact the respective event representatives.

What is the primary goal of Portage Biotech?

Portage aims to develop therapies that enhance patient lives and survival through targeted immuno-oncology treatments.